Transarterial radioembolization (TARE) is done to treat inoperable liver tumors, especially hepatocellular carcinoma (HCC) or liver metastases from other cancers. By introducing radioactive microspheres straight into the liver's bloodstream, it targets tumors and gives high-dose localized radiation without harming healthy tissue.

If you suffer from chronic upper abdominal pain, unexplained weight loss, exhaustion, jaundice, or loss of appetite , you should consult a physician, particularly if you have a history of cancer or liver illness. Early evaluation can help determine if TARE or another treatment is appropriate.

Physicians use imaging and a lung shunt test to map hepatic vessels and guarantee safe radiation administration in order to get ready for TARE. It may be necessary for patients to fast and modify their medication before to the surgery.

In TARE, the surgeon inserts a catheter through the groin or wrist into the hepatic artery supplying the liver tumour. Tiny radioactive beads (usually Yttrium-90) are delivered directly to the tumour site through the catheter. These beads release localised radiation, destroying cancer cells while reducing damage to healthy tissue.

Transarterial radioembolization (TARE) usually takes 1-3 hours, depending on the number of tumors to be treated and the complexity of the process.

• Liver damage or inflammation
• Gastrointestinal issues such as nausea, vomiting, or ulceration
• Fever, pain, and fatigue.
• Infection or bleeding at the catheter insertion site.

TARE improves symptoms by directly delivering targeted radiation to liver tumors while preserving healthy tissue. Compared to regular surgery, it is less painful and requires less recovery time.

Following TARE, post-operative recovery requires a few days of hospital monitoring to control fever, nausea, and pain. With routine follow-up imaging to evaluate tumor response, most patients can resume their regular activities within 1 to 2 weeks, however some may have post-embolization syndrome.

TARE has demonstrated positive results for patients with hepatocellular carcinoma (HCC), with tumor response rates of 40\u201360%. However, the success rate varies depending on the kind, size, and location of the tumor.